Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    gog-0127w
Show Display Options
Rank Status Study
1 Completed Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Small Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Recurrent Cervical Carcinoma;   Stage III Cervical Cancer;   Stage IVA Cervical Cancer;   Stage IVB Cervical Cancer
Interventions: Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Biological: Pegfilgrastim;   Drug: Topotecan Hydrochloride;   Drug: Veliparib

Study has passed its completion date and status has not been verified in more than two years.